News
Valeant swings back after Allergan assault - The Globe and Mail
www.theglobeandmail.com
Latest move boosts bid for Botox maker to nearly $50-billion
Teva to buy U.S. drug developer Auspex Pharma for $3.5 bln | Reuters
www.reuters.com
Bernstein analyst Aaron Gal said the acquisition was a good strategic fit for Teva as the company looks to boost growth, and also leaves ...
Allergan to pay $600-mn fine in Botox probe - The Economic ...m.economictimes.com › News › International
economictimes.indiatimes.com
... sales, may generate an additional $1 billion with use in migraines, according to Aaron Gal, an analyst at Sanford C Bernstein in New York.
Aaron Gal | Benzinga
www.benzinga.com
In a report published Wednesday, Bernstein Research analyst Aaron Gal reiterated an Outperform rating on Momenta …s (NASDAQ: MNTA), and raised the price
sorted by relevance / date